Calgary's Syantra Pioneers New Breast Cancer Screening in Major U.S. Study, Elevating Local Life Sciences
Calgary Innovation Targets Critical Gaps
Calgary-based Syantra Inc., a leader in biotechnology, is making significant strides in breast cancer detection. Its Onco-ID™ Breast, a pioneering whole blood mRNA test for high-risk women, is now entering crucial clinical studies with recruitment launched by Vincere Cancer Center in Scottsdale, Arizona. This multi-center study, funded by the U.S. Congressionally Directed Medical Research Program (CDMRP), underscores a vital collaboration between the University of Calgary and Weill Cornell Medicine, with Syantra co-founder Dr. Kristina Rinker of UCalgary serving as co-Principal Investigator.
The Urgent Need for Earlier Detection
The study aims to enroll 2,000 women aged 30-75, specifically focusing on those with dense breasts, a condition affecting 40-50% of women that complicates traditional mammography. Early detection is paramount: breast cancer boasts over a 99% five-year survival rate when found at its earliest invasive stage. Despite a 43% drop in U.S. mortality rates between 1989 and 2020, an estimated 42,170 women are projected to die from the disease in 2025. The challenge is growing, with incidence rates increasing in younger women and non-Hispanic Black women facing a 40% higher mortality rate.
Calgary's Life Sciences Sector on the Rise
Syantra's leadership in this global effort highlights the remarkable growth of Calgary's life sciences sector, a key pillar in the city's economic diversification strategy. With over 120 companies, this sector contributes significantly to Alberta's GDP ($4.8 billion) and supports over 34,400 jobs. The University of Calgary, a top-five national research institution, plays a pivotal role, providing critical infrastructure through its Life Sciences Innovation Hub. This innovation ecosystem is further bolstered by the recent opening of the Arthur J.E. Child Comprehensive Cancer Centre, Canada's largest facility of its kind, solidifying Calgary's position as a hub for oncology research and medical breakthroughs.
A Healthier Future, Forged in Calgary
The success of Syantra's Onco-ID™ Breast test could revolutionize breast cancer screening, offering a less invasive, more effective tool, particularly for vulnerable populations. This progress not only signifies a profound advancement in global health but also firmly plants Calgary at the forefront of medical innovation, embodying the city's commitment to creating a healthier future and a resilient economy.
